Abbott Laboratories (ABT) Cost of Revenue (2009 - 2026)

Abbott Laboratories has disclosed Cost of Revenue across 18 years of filings, most recently posting $4.9 billion for Q1 2026.

• Cost of Revenue for Q1 2026 came in at $4.9 billion, up 9.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $19.7 billion (up 5.5% YoY), and the FY2025 annual result was $19.3 billion, up 3.28% from the prior year.
• Cost of Revenue came in at $4.9 billion for Q1 2026 at Abbott Laboratories, down from $4.9 billion in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $5.1 billion in Q3 2025 to a low of $4.3 billion in Q1 2023.
• The 5-year median for Cost of Revenue is $4.6 billion (2022), against an average of $4.7 billion.
• Across the five-year window, Cost of Revenue rose 13.32% in 2022 and retreated 13.15% in 2023, its largest moves.
• Abbott Laboratories' Cost of Revenue stood at $4.6 billion in 2022, then fell by 0.81% to $4.6 billion in 2023, then climbed by 8.47% to $4.9 billion in 2024, then dropped by 0.4% to $4.9 billion in 2025, then slipped by 0.65% to $4.9 billion in 2026.
• The last three Cost of Revenue figures came in at $4.9 billion (Q1 2026), $4.9 billion (Q4 2025), and $5.1 billion (Q3 2025), per Business Quant data.